550 related articles for article (PubMed ID: 33730454)
1. Two Randomized Trials of Neutralizing Antibodies to Prevent HIV-1 Acquisition.
Corey L; Gilbert PB; Juraska M; Montefiori DC; Morris L; Karuna ST; Edupuganti S; Mgodi NM; deCamp AC; Rudnicki E; Huang Y; Gonzales P; Cabello R; Orrell C; Lama JR; Laher F; Lazarus EM; Sanchez J; Frank I; Hinojosa J; Sobieszczyk ME; Marshall KE; Mukwekwerere PG; Makhema J; Baden LR; Mullins JI; Williamson C; Hural J; McElrath MJ; Bentley C; Takuva S; Gomez Lorenzo MM; Burns DN; Espy N; Randhawa AK; Kochar N; Piwowar-Manning E; Donnell DJ; Sista N; Andrew P; Kublin JG; Gray G; Ledgerwood JE; Mascola JR; Cohen MS;
N Engl J Med; 2021 Mar; 384(11):1003-1014. PubMed ID: 33730454
[TBL] [Abstract][Full Text] [Related]
2. Feasibility and Successful Enrollment in a Proof-of-Concept HIV Prevention Trial of VRC01, a Broadly Neutralizing HIV-1 Monoclonal Antibody.
Edupuganti S; Mgodi N; Karuna ST; Andrew P; Rudnicki E; Kochar N; deCamp A; De La Grecca R; Anderson M; Karg C; Tindale I; Greene E; Broder GB; Lucas J; Hural J; Gallardo-Cartagena JA; Gonzales P; Frank I; Sobieszczyk M; Gomez Lorenzo MM; Burns D; Anderson PL; Miner MD; Ledgerwood J; Mascola JR; Gilbert PB; Cohen MS; Corey L;
J Acquir Immune Defic Syndr; 2021 May; 87(1):671-679. PubMed ID: 33587505
[TBL] [Abstract][Full Text] [Related]
3. A Phase 2b Study to Evaluate the Safety and Efficacy of VRC01 Broadly Neutralizing Monoclonal Antibody in Reducing Acquisition of HIV-1 Infection in Women in Sub-Saharan Africa: Baseline Findings.
Mgodi NM; Takuva S; Edupuganti S; Karuna S; Andrew P; Lazarus E; Garnett P; Shava E; Mukwekwerere PG; Kochar N; Marshall K; Rudnicki E; Juraska M; Anderson M; Karg C; Tindale I; Greene E; Luthuli N; Baepanye K; Hural J; Gomez Lorenzo MM; Burns D; Miner MD; Ledgerwood J; Mascola JR; Donnell D; Cohen MS; Corey L;
J Acquir Immune Defic Syndr; 2021 May; 87(1):680-687. PubMed ID: 33587510
[TBL] [Abstract][Full Text] [Related]
4. Safety, pharmacokinetics, and immunological activities of multiple intravenous or subcutaneous doses of an anti-HIV monoclonal antibody, VRC01, administered to HIV-uninfected adults: Results of a phase 1 randomized trial.
Mayer KH; Seaton KE; Huang Y; Grunenberg N; Isaacs A; Allen M; Ledgerwood JE; Frank I; Sobieszczyk ME; Baden LR; Rodriguez B; Van Tieu H; Tomaras GD; Deal A; Goodman D; Bailer RT; Ferrari G; Jensen R; Hural J; Graham BS; Mascola JR; Corey L; Montefiori DC; ;
PLoS Med; 2017 Nov; 14(11):e1002435. PubMed ID: 29136037
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetic serum concentrations of VRC01 correlate with prevention of HIV-1 acquisition.
Seaton KE; Huang Y; Karuna S; Heptinstall JR; Brackett C; Chiong K; Zhang L; Yates NL; Sampson M; Rudnicki E; Juraska M; deCamp AC; Edlefsen PT; Mullins JI; Williamson C; Rossenkhan R; Giorgi EE; Kenny A; Angier H; Randhawa A; Weiner JA; Rojas M; Sarzotti-Kelsoe M; Zhang L; Sawant S; Ackerman ME; McDermott AB; Mascola JR; Hural J; McElrath MJ; Andrew P; Hidalgo JA; Clark J; Laher F; Orrell C; Frank I; Gonzales P; Edupuganti S; Mgodi N; Corey L; Morris L; Montefiori D; Cohen MS; Gilbert PB; Tomaras GD
EBioMedicine; 2023 Jul; 93():104590. PubMed ID: 37300931
[TBL] [Abstract][Full Text] [Related]
6. Prevention efficacy of the broadly neutralizing antibody VRC01 depends on HIV-1 envelope sequence features.
Juraska M; Bai H; deCamp AC; Magaret CA; Li L; Gillespie K; Carpp LN; Giorgi EE; Ludwig J; Molitor C; Hudson A; Williamson BD; Espy N; Simpkins B; Rudnicki E; Shao D; Rossenkhan R; Edlefsen PT; Westfall DH; Deng W; Chen L; Zhao H; Bhattacharya T; Pankow A; Murrell B; Yssel A; Matten D; York T; Beaume N; Gwashu-Nyangiwe A; Ndabambi N; Thebus R; Karuna ST; Morris L; Montefiori DC; Hural JA; Cohen MS; Corey L; Rolland M; Gilbert PB; Williamson C; Mullins JI
Proc Natl Acad Sci U S A; 2024 Jan; 121(4):e2308942121. PubMed ID: 38241441
[TBL] [Abstract][Full Text] [Related]
7. Infusion Reactions After Receiving the Broadly Neutralizing Antibody VRC01 or Placebo to Reduce HIV-1 Acquisition: Results From the Phase 2b Antibody-Mediated Prevention Randomized Trials.
Takuva S; Karuna ST; Juraska M; Rudnicki E; Edupuganti S; Anderson M; De La Grecca R; Gaudinski MR; Sehurutshi A; Orrell C; Naidoo L; Valencia J; Villela LM; Walsh SR; Andrew P; Karg C; Randhawa A; Hural J; Gomez Lorenzo MM; Burns DN; Ledgerwood J; Mascola JR; Cohen M; Corey L; Mngadi K; Mgodi NM;
J Acquir Immune Defic Syndr; 2022 Apr; 89(4):405-413. PubMed ID: 34923559
[TBL] [Abstract][Full Text] [Related]
8. Safety, acceptability, and pharmacokinetics of a monoclonal antibody-based vaginal multipurpose prevention film (MB66): A Phase I randomized trial.
Politch JA; Cu-Uvin S; Moench TR; Tashima KT; Marathe JG; Guthrie KM; Cabral H; Nyhuis T; Brennan M; Zeitlin L; Spiegel HML; Mayer KH; Whaley KJ; Anderson DJ
PLoS Med; 2021 Feb; 18(2):e1003495. PubMed ID: 33534791
[TBL] [Abstract][Full Text] [Related]
9. Safety and efficacy of VRC01 broadly neutralising antibodies in adults with acutely treated HIV (RV397): a phase 2, randomised, double-blind, placebo-controlled trial.
Crowell TA; Colby DJ; Pinyakorn S; Sacdalan C; Pagliuzza A; Intasan J; Benjapornpong K; Tangnaree K; Chomchey N; Kroon E; de Souza MS; Tovanabutra S; Rolland M; Eller MA; Paquin-Proulx D; Bolton DL; Tokarev A; Thomas R; Takata H; Trautmann L; Krebs SJ; Modjarrad K; McDermott AB; Bailer RT; Doria-Rose N; Patel B; Gorelick RJ; Fullmer BA; Schuetz A; Grandin PV; O'Connell RJ; Ledgerwood JE; Graham BS; Tressler R; Mascola JR; Chomont N; Michael NL; Robb ML; Phanuphak N; Ananworanich J;
Lancet HIV; 2019 May; 6(5):e297-e306. PubMed ID: 31000477
[TBL] [Abstract][Full Text] [Related]
10. Safety, tolerability, pharmacokinetics, and immunological activity of dual-combinations and triple-combinations of anti-HIV monoclonal antibodies PGT121, PGDM1400, 10-1074, and VRC07-523LS administered intravenously to HIV-uninfected adults: a phase 1 randomised trial.
Sobieszczyk ME; Mannheimer S; Paez CA; Yu C; Gamble T; Theodore DA; Chege W; Yacovone M; Hanscom B; Heptinstall J; Seaton KE; Zhang L; Miner MD; Eaton A; Weiner JA; Mayer K; Kalams S; Stephenson K; Julg B; Caskey M; Nussenzweig M; Gama L; Barouch DH; Ackerman ME; Tomaras GD; Huang Y; Montefiori D;
Lancet HIV; 2023 Oct; 10(10):e653-e662. PubMed ID: 37802566
[TBL] [Abstract][Full Text] [Related]
11. Effect of HIV Antibody VRC01 on Viral Rebound after Treatment Interruption.
Bar KJ; Sneller MC; Harrison LJ; Justement JS; Overton ET; Petrone ME; Salantes DB; Seamon CA; Scheinfeld B; Kwan RW; Learn GH; Proschan MA; Kreider EF; Blazkova J; Bardsley M; Refsland EW; Messer M; Clarridge KE; Tustin NB; Madden PJ; Oden K; O'Dell SJ; Jarocki B; Shiakolas AR; Tressler RL; Doria-Rose NA; Bailer RT; Ledgerwood JE; Capparelli EV; Lynch RM; Graham BS; Moir S; Koup RA; Mascola JR; Hoxie JA; Fauci AS; Tebas P; Chun TW
N Engl J Med; 2016 Nov; 375(21):2037-2050. PubMed ID: 27959728
[TBL] [Abstract][Full Text] [Related]
12. Broadly neutralizing monoclonal antibodies for HIV prevention.
Miner MD; Corey L; Montefiori D
J Int AIDS Soc; 2021 Nov; 24 Suppl 7(Suppl 7):e25829. PubMed ID: 34806308
[TBL] [Abstract][Full Text] [Related]
13. Neutralization profiles of HIV-1 viruses from the VRC01 Antibody Mediated Prevention (AMP) trials.
Mkhize NN; Yssel AEJ; Kaldine H; van Dorsten RT; Woodward Davis AS; Beaume N; Matten D; Lambson B; Modise T; Kgagudi P; York T; Westfall DH; Giorgi EE; Korber B; Anthony C; Mapengo RE; Bekker V; Domin E; Eaton A; Deng W; DeCamp A; Huang Y; Gilbert PB; Gwashu-Nyangiwe A; Thebus R; Ndabambi N; Mielke D; Mgodi N; Karuna S; Edupuganti S; Seaman MS; Corey L; Cohen MS; Hural J; McElrath MJ; Mullins JI; Montefiori D; Moore PL; Williamson C; Morris L
PLoS Pathog; 2023 Jun; 19(6):e1011469. PubMed ID: 37384759
[TBL] [Abstract][Full Text] [Related]
14. Safety, Tolerability, and Pharmacokinetics of the Broadly Neutralizing Human Immunodeficiency Virus (HIV)-1 Monoclonal Antibody VRC01 in HIV-Exposed Newborn Infants.
Cunningham CK; McFarland EJ; Morrison RL; Capparelli EV; Safrit JT; Mofenson LM; Mathieson B; Valentine ME; Perlowski C; Smith B; Hazra R; Purdue L; Muresan P; Harding PA; Mbengeranwa T; Robinson LG; Wiznia A; Theron G; Lin B; Bailer RT; Mascola JR; Graham BS;
J Infect Dis; 2020 Jul; 222(4):628-636. PubMed ID: 31681963
[TBL] [Abstract][Full Text] [Related]
15. Rectal tissue and vaginal tissue from intravenous VRC01 recipients show protection against ex vivo HIV-1 challenge.
Astronomo RD; Lemos MP; Narpala SR; Czartoski J; Fleming LB; Seaton KE; Prabhakaran M; Huang Y; Lu Y; Westerberg K; Zhang L; Gross MK; Hural J; Tieu HV; Baden LR; Hammer S; Frank I; Ochsenbauer C; Grunenberg N; Ledgerwood JE; Mayer K; Tomaras G; McDermott AB; McElrath MJ
J Clin Invest; 2021 Aug; 131(16):. PubMed ID: 34166231
[TBL] [Abstract][Full Text] [Related]
16. Participants' characteristics and motivations to screen for HIV vaccine and monoclonal antibody trials in KwaZulu-Natal, South Africa.
Hanass-Hancock J; Carpenter B; Reddy T; Nzuza A; Gaffoor Z; Goga A; Andrasik M
Trials; 2021 Dec; 22(1):897. PubMed ID: 34895272
[TBL] [Abstract][Full Text] [Related]
17. Safety and pharmacokinetics of VRC07-523LS administered via different routes and doses (HVTN 127/HPTN 087): A Phase I randomized clinical trial.
Walsh SR; Gay CL; Karuna ST; Hyrien O; Skalland T; Mayer KH; Sobieszczyk ME; Baden LR; Goepfert PA; Del Rio C; Pantaleo G; Andrew P; Karg C; He Z; Lu H; Paez CA; Baumblatt JAG; Polakowski LL; Chege W; Anderson MA; Janto S; Han X; Huang Y; Dumond J; Ackerman ME; McDermott AB; Flach B; Piwowar-Manning E; Seaton K; Tomaras GD; Montefiori DC; Gama L; Mascola JR;
PLoS Med; 2024 Jun; 21(6):e1004329. PubMed ID: 38913710
[TBL] [Abstract][Full Text] [Related]
18. A Randomised Clinical Trial of the Safety and Pharmacokinetics of VRC07-523LS Administered via Different Routes and Doses (HVTN 127/HPTN 087).
Walsh SR; Gay CL; Karuna ST; Hyrien O; Skalland T; Mayer KH; Sobieszczyk ME; Baden LR; Goepfert PA; Del Rio C; Pantaleo G; Andrew P; Karg C; He Z; Lu H; Paez CA; Baumblatt JAG; Polakowski LL; Chege W; Janto S; Han X; Huang Y; Dumond J; Ackerman ME; McDermott AB; Flach B; Piwowar-Manning E; Seaton K; Tomaras GD; Montefiori DC; Gama L; Mascola JR;
medRxiv; 2024 Jan; ():. PubMed ID: 38260276
[TBL] [Abstract][Full Text] [Related]
19. Efficacy, safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir for HIV pre-exposure prophylaxis in transgender women: a secondary analysis of the HPTN 083 trial.
Marzinke MA; Hanscom B; Wang Z; Safren SA; Psaros C; Donnell D; Richardson PA; Sullivan P; Eshleman SH; Jennings A; Feliciano KG; Jalil E; Coutinho C; Cardozo N; Maia B; Khan T; Singh Y; Middelkoop K; Franks J; Valencia J; Sanchez N; Lucas J; Rooney JF; Rinehart AR; Ford S; Adeyeye A; Cohen MS; McCauley M; Landovitz RJ; Grinsztejn B;
Lancet HIV; 2023 Nov; 10(11):e703-e712. PubMed ID: 37783219
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics and predicted neutralisation coverage of VRC01 in HIV-uninfected participants of the Antibody Mediated Prevention (AMP) trials.
Huang Y; Naidoo L; Zhang L; Carpp LN; Rudnicki E; Randhawa A; Gonzales P; McDermott A; Ledgerwood J; Lorenzo MMG; Burns D; DeCamp A; Juraska M; Mascola J; Edupuganti S; Mgodi N; Cohen M; Corey L; Andrew P; Karuna S; Gilbert PB; Mngadi K; Lazarus E
EBioMedicine; 2021 Feb; 64():103203. PubMed ID: 33493795
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
